Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process.

The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of a New Drug Application, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA.

Pharmaxis previously agreed on the trial design with the European regulatory agency (EMEA). This trial will therefore form the basis of a marketing application in both the U.S. and Europe.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, double-blind investigation of Bronchitol twice daily in approximately 350 adults with bronchiectasis. Participants will be treated for 52 weeks and the primary endpoints are reduction in frequency of exacerbations and improvement in quality of life. Secondary endpoints include time to first exacerbation and duration of exacerbation. Additional secondary endpoints are antibiotic use, sputum volume, exercise tolerance and lung function measurements. The trial includes health economic analysis and will be conducted in centers across Europe and the U.S.

This trial is the second Phase III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a successful shorter trial reported last year.

Pharmaxis CEO, Alan Robertson, said the company was pleased to have concluded its discussions with the FDA and the EMEA.

''We believe this phase 3 trial design will allow us to thoroughly demonstrate the clinical benefits of Bronchitol in a patient populat
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Following a bipartisan vote in ... H.R. 284, the Medicare DMEPOS Competitive Bidding Improvement ... Homecare (AAHomecare) released a statement praising the Committee,s ... the legislation. "Today,s mark-up of the ... and Means Committee is a critical step forward ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... Feb. 27, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare diseases, joins ... European Organisation for Rare Diseases™ (EURORDIS™), The Global ... observing Rare Disease Day. On the ... industry, and other participants conduct special events to ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... to 88% Efficacy, SEOUL, Korea, March 28, 2007 ... it has completed a 340 patient phase,2b "at-home" ... (12,hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor ... the,U.S. was a randomized, double-blind, placebo controlled study,designed ...
... advantages of nifedipine,GITS therapy , , ... Two recently,published articles in the Journal of ... of the long-acting calcium channel,blocker (CCB) nifedipine ... blood pressure lowing effect. A first,publication from ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,Its New Long Acting Drug For Erectile Dysfunction 2Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,Its New Long Acting Drug For Erectile Dysfunction 3Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,Its New Long Acting Drug For Erectile Dysfunction 4Calcium Channel Blocker Adalat GITS Offer Additional Benefits 2Calcium Channel Blocker Adalat GITS Offer Additional Benefits 3
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... 28, 2015 The Mesothelioma Applied ... awards at the International Symposium on Malignant Mesothelioma on ... at the Hyatt Regency Bethesda in Bethesda, Maryland. The ... work and commitment to the mission to cure mesothelioma. ... will be presented to Miriam Ratner. Miriam runs the ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 ... organization has sponsored visitor health insurance programs for visitors ... years. Most Indian elderly parents traveling to the United ... such as diabetes and blood pressure. These diseases are ... not even list them as medical conditions. There were ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
Breaking Medicine News(10 mins):Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... West Bengal was first refused treatment by government hospitals ... human rights group intervened to unshackle him, reports said ... by the Association for the Protection of Democratic Rights ... North 24 Parganas district freed., ,Debnath had developed ...
... Watch had explored the physiology// of hot flashes experienced by ... flashes are well known to most menopausal women—and to many ... tend to come on suddenly and last from one to ... to a feeling of being on fire. , ,Although ...
... authorities are pouring cold water on hopes for a new drug ... and Drug Administration (FDA) wants more studies to be done on ... find out what long-term side effects the drug may induce, the ... "female Viagra" as it promises to restore healthy sexual appetites to ...
... pollution levels may have an increased chance of a heart ... ,The research done by scientists from Loma Linda University had ... Environmental Health Perspectives. Their research findings suggest that the rate ... more if they happen to live in areas that have ...
... ,Chennai's Adyar Cancer Institute director Dr.V. Shanta is among ... was awarded the prize for public service and her "untiring ... and compassion for the study and treatment of cancer// in ... She has also won a number of national and international ...
... from kidney diseases may have increased risk of death ... from Johns Hopkins University School of Medicine have found ... peritoneal dialysis over hemodialysis increases their risk of dying ... published in the journal Annals of Internal Medicine online ...
Cached Medicine News:Health News:Insight for Hot Flashes In Postmenopausal Women 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Air Pollution Increases Risk For Heart Disease In Women 2Health News:Magsaysay Award for Dr.Shanta from Chennai Cancer Institute 2Health News:Choice Of Treatment Increases Risk Of Death In Kidney Disease 2
... TEARS is an all-natural moisturizing mist for ... of Dr. William Mathers, from Oregon Health ... study of NATURE'S TEARS (2000) and dry ... mist doubled the moisture volume of the ...
151 channels cover the entire head with a high density, with provisions for the eyes and ears. Patients and subjects are examined in a comfortable seated position or laying down....
... is achieved using an increased tilt angle ... patient bed. The patient preparation can be ... case of an emergency the patient can ... for e.g. resuscitation purposes. The integrated neck ...
... Model Practice Eye can be used for demonstration ... ophthalmoscopy, non-contact fundus biomicroscopy. , ,The ... rubber which closely resembles the human eye size ... the sclera. The lens and pupil arrangement ...
Medicine Products: